Investigators presented 12-month phase 2 data on subretinal OCU410 gene therapy in patients with geographic atrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results